Acute myeloid leukemia: current progress and future directions
H Kantarjian, T Kadia, C DiNardo, N Daver… - Blood cancer …, 2021 - nature.com
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML)
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …
is occurring rapidly. Since 2017, nine agents have been approved for various indications in …
[HTML][HTML] Current therapy and drug resistance in metastatic castration-resistant prostate cancer
M Cai, XL Song, XA Li, M Chen, J Guo, DH Yang… - Drug Resistance …, 2023 - Elsevier
Castration-resistant prostate cancer (CRPC), especially metastatic castration-resistant
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …
prostate cancer (mCRPC) is one of the most prevalent malignancies and main cause of …
Cancer therapy shapes the fitness landscape of clonal hematopoiesis
Acquired mutations are pervasive across normal tissues. However, understanding of the
processes that drive transformation of certain clones to cancer is limited. Here we study this …
processes that drive transformation of certain clones to cancer is limited. Here we study this …
Non-genetic mechanisms of therapeutic resistance in cancer
JC Marine, SJ Dawson, MA Dawson - Nature Reviews Cancer, 2020 - nature.com
Therapeutic resistance continues to be an indominable foe in our ambition for curative
cancer treatment. Recent insights into the molecular determinants of acquired treatment …
cancer treatment. Recent insights into the molecular determinants of acquired treatment …
[HTML][HTML] Exosome-based liquid biopsies in cancer: opportunities and challenges
W Yu, J Hurley, D Roberts, SK Chakrabortty… - Annals of …, 2021 - Elsevier
Liquid biopsy in cancer has gained momentum in clinical research and is experiencing a
boom for a variety of applications. There are significant efforts to utilize liquid biopsies in …
boom for a variety of applications. There are significant efforts to utilize liquid biopsies in …
[HTML][HTML] Drug resistance and combating drug resistance in cancer
Cancer is the second leading cause of death in the US. Current major treatments for cancer
management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy …
management include surgery, cytotoxic chemotherapy, targeted therapy, radiation therapy …
Multidrug resistance in cancer: understanding molecular mechanisms, immunoprevention and therapeutic approaches
Cancer is one of the leading causes of death worldwide. Several treatments are available for
cancer treatment, but many treatment methods are ineffective against multidrug-resistant …
cancer treatment, but many treatment methods are ineffective against multidrug-resistant …
Targeting FLT3 mutations in AML: review of current knowledge and evidence
Genomic investigations of acute myeloid leukemia (AML) have demonstrated that several
genes are recurrently mutated, leading to new genomic classifications, predictive …
genes are recurrently mutated, leading to new genomic classifications, predictive …
The multi-factorial nature of clinical multidrug resistance in cancer
Curative cancer therapy remains a major challenge particularly in cancers displaying
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …
Acute myeloid leukaemia
NJ Short, ME Rytting, JE Cortes - The Lancet, 2018 - thelancet.com
For several decades, few substantial therapeutic advances have been made for patients
with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen …
with acute myeloid leukaemia. However, since 2017 unprecedented growth has been seen …